Proceedings and data from The Schizophrenia Summit: a critical appraisal to improve the management of Schizophrenia

J Clin Psychiatry. 2009:70 Suppl 1:4-46.

Abstract

In mid-February 2008, a panel of 10 nationally recognized schizophrenia research experts was assembled in a Schizophrenia Summit to focus on controversies that exist in treating patients with schizophrenia. The current literature related to the diagnosis and etiopathology of schizophrenia was evaluated regarding the identification of a prodromal phase, brain changes, cognitive impairments, genetic factors, and use of neuroimaging in patients with schizophrenia. Further, consideration was given to evidence supporting the neuroprotective benefits of atypical antipsychotic medications, the benefits of treating patients during the prodromal period, the use of combination antipsychotic medications, the need to improve cognitive function, and the management of substance abuse. Summit faculty member opinion is compared with field survey results, and recommendations are made for future research.

Publication types

  • Congress
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Antipsychotic Agents / adverse effects
  • Antipsychotic Agents / therapeutic use*
  • Brain / drug effects
  • Brain / pathology
  • Cognition Disorders / diagnosis
  • Cognition Disorders / drug therapy
  • Cognition Disorders / genetics
  • Comorbidity
  • Diagnostic Imaging
  • Drug Therapy, Combination
  • Early Diagnosis
  • Genetic Predisposition to Disease
  • Humans
  • Schizophrenia / diagnosis
  • Schizophrenia / drug therapy*
  • Schizophrenia / epidemiology
  • Schizophrenia / genetics
  • Schizotypal Personality Disorder / diagnosis
  • Schizotypal Personality Disorder / drug therapy
  • Schizotypal Personality Disorder / genetics
  • Substance-Related Disorders / diagnosis
  • Substance-Related Disorders / epidemiology

Substances

  • Antipsychotic Agents